WO2009074995A1 - Compositions à croquer de citrate de sildénafil au goût masqué - Google Patents
Compositions à croquer de citrate de sildénafil au goût masqué Download PDFInfo
- Publication number
- WO2009074995A1 WO2009074995A1 PCT/IN2008/000049 IN2008000049W WO2009074995A1 WO 2009074995 A1 WO2009074995 A1 WO 2009074995A1 IN 2008000049 W IN2008000049 W IN 2008000049W WO 2009074995 A1 WO2009074995 A1 WO 2009074995A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sildenafil
- composition
- sildenafil citrate
- taste
- complex
- Prior art date
Links
- 235000019640 taste Nutrition 0.000 title claims abstract description 48
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229960002639 sildenafil citrate Drugs 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims description 53
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 21
- 230000000873 masking effect Effects 0.000 claims abstract description 19
- 229960003310 sildenafil Drugs 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 239000007910 chewable tablet Substances 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 235000019658 bitter taste Nutrition 0.000 claims abstract description 9
- 239000000796 flavoring agent Substances 0.000 claims abstract description 9
- 235000019634 flavors Nutrition 0.000 claims abstract description 9
- 229940068682 chewable tablet Drugs 0.000 claims abstract description 8
- 238000005342 ion exchange Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 27
- 230000008569 process Effects 0.000 claims description 18
- 239000011230 binding agent Substances 0.000 claims description 13
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
- 239000004925 Acrylic resin Substances 0.000 claims description 10
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 10
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 10
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 10
- 125000002091 cationic group Chemical group 0.000 claims description 9
- 108010011485 Aspartame Proteins 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 239000004376 Sucralose Substances 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 7
- 239000000605 aspartame Substances 0.000 claims description 7
- 235000010357 aspartame Nutrition 0.000 claims description 7
- 229960003438 aspartame Drugs 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 235000019408 sucralose Nutrition 0.000 claims description 7
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 239000003086 colorant Substances 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- -1 sweetners Substances 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 230000007246 mechanism Effects 0.000 claims description 5
- 229940069328 povidone Drugs 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 229920003124 powdered cellulose Polymers 0.000 claims description 3
- 235000019814 powdered cellulose Nutrition 0.000 claims description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 230000001050 lubricating effect Effects 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 abstract description 16
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000007888 film coating Substances 0.000 abstract description 2
- 238000009501 film coating Methods 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000003456 ion exchange resin Substances 0.000 abstract description 2
- 229920003303 ion-exchange polymer Polymers 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000000576 coating method Methods 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 11
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 6
- 229960002303 citric acid monohydrate Drugs 0.000 description 6
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 6
- 210000005226 corpus cavernosum Anatomy 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000003094 microcapsule Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000005461 lubrication Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 3
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 3
- 235000019888 Vivapur Nutrition 0.000 description 3
- 239000008199 coating composition Substances 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical group C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 2
- 229960000939 metoprolol succinate Drugs 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920002959 polymer blend Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000004648 relaxation of smooth muscle Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229940094720 viagra Drugs 0.000 description 2
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 101150085511 PEDS1 gene Proteins 0.000 description 1
- 102100037592 Plasmanylethanolamine desaturase Human genes 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 108091005708 gustatory receptors Proteins 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007912 modified release tablet Substances 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229960000718 piperazine citrate Drugs 0.000 description 1
- 229920003199 poly(diethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
Definitions
- the present invention provides novel chewable immediate release compositions comprising sildenafil citrate wherein the bitter taste of sildenafil has been masked by forming a sildenafil mask complex
- the masking agent comprises of a mixture of polyacrylic resin, carbomer and powdered microcrystalline cellulose.
- the sildenafil gets entrapped in the polyacrylic resin which has free exchange sites and a cationic exchange occurs.
- the carbomer serves as a binder to strengthen the complex formation whereas the powdered microcrystalline cellulose is a filler.
- the said composition further comprises other excipients like mannitol which serves as the base for a chewable tablet, disintegrants, binders, lubricants, glidants and flavours.
- Sildenafil citrate is a selective inhibitor of cyclic guanosine monophosphate (cGMP)- specific phosphodiesterase type 5 (PDE5), commercially developed by Pfizer, Inc. as VIAGRA R .
- Sildenafil citrate is designated chemically as l-[[3-(6,7-dihydro-l-methyl-7- oxo-3-propyl-lH-pyrazolo[4,3- ⁇ pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl piperazine citrate, having a molecular weight of 666.7, and the following chemical structure:
- Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 mg/ml in water.
- NO nitric oxide
- cGMP cyclic guanosine monophosphate
- Sildenafil has no direct relaxant effect on isolated human corpus cavernosum, but enhances the effect of nitric oxide by inhibiting phosphodiesterase type 5, which is responsible for degradation of cGMP in the corpus cavernosum.
- sildenafil When sexual stimulation causes local release of NO, inhibition of PDES by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil at recommended doses has no effect in the absence of sexual stimulation.
- sildenafil citrate has a very bitter taste and hence tablets such as Viagra R , which are commercially available are film coated.
- the film coating masks any bitter taste in the mouth and these tablets have to be taken with water.
- chewable tablets which are usually uncoated, there is a need to mask the bitter taste of sildenafil as they are chewed and remain in contact with the taste receptors in the mouth for a longer period of time.
- formulations relating to various processes used for taste masking of ingredients are known priori art.
- US Patent No. 6,197,348 describes a dosage form that utilizes encapsulated particles coated with polymers, such as Eudragit RS and Eudragit RL.
- Taste masking is achieved as a result of the polymer coatings and a liquid suspending medium having a pH that is adjusted to a point where the active ingredient is insoluble.
- the thickness and type of coating is not sufficient for taste masking.
- EP 0458751 discloses compositions containing a core that includes a cyclic amino acid compound.
- the core is coated with polymeric film forming compounds and hydrophilic fats' fatty acids and waxes.
- US Patent No. 4,800,087 discloses a taste masked composition in a chewable dosage form having a controlled release profile.
- the invention utilizes a combination of polymers to achieve a taste masking coating suitable for incorporation into a chewable dosage form.
- the composition contains microcapsules which are composed of an active ingredient and a polymer mixture coating having a sufficient elasticity to withstand chewing.
- the polymeric coating mixture includes one high temperature film forming copolymer and one low temperature film forming copolymer.
- US Patent No. 6,139,865 discloses a taste masked microcapsule composition of water soluble active ingredients.
- the water soluble active ingredients are coacervated in the polymeric material.
- This technique suffers from several disadvantages. For example, the technique requires the use of hydrocarbons and other organic solvents, such as; cyclohexane. These solvents are explosive and present problems in large scale manufacturing.
- US Application 2002/064563 discloses a taste masked composition of topiramate and a process for its preparation. The process includes preparing core particles which include the active ingredient topiramate, coating with a taste masked mixture to form coated particles, and drying the coated particles.
- US Patent No. 6,106,861 discloses a multiparticulate disintegrating tablet which includes excipients and an active ingredient in the form of microcrystals. Only a limited number of active ingredients can be commercially made in the form of microcrystals, and specifically, amorphous powders cannot be utilized in this process.
- WO 01/35930 discloses a process for taste masking by granulation of the active ingredient with an aqueous admixture that includes a neutral methacrylic acid ester copolymers and a binder. Taste masking can only be achieved for moderately bitter and poorly soluble active ingredients, but is ineffective for highly bitter and/or soluble active ingredients.
- US Patent No. 5,084,278 describes a chewable taste masked pharmaceutical composition having a controlled release profile.
- the composition comprises microcapsules with are made up of an active ingredient core coated with a polymer mixture.
- the coating includes a blend of ethyl cellulose and polymethacrylic acid ester copolymers.
- US Patent No. 6,136,347 describes a pharmaceutical composition which comprises microcapsules wherein the active ingredient is microencapsulated within the microcapsule wall.
- the active ingredient is present as an anhydrate or its free base fond.
- the composition further utilizes an oily suspension as a vehicle for suspending microparticles coated with a combination of water soluble and water insoluble polymers' thus preventing the interaction of water.
- this dosage form suffers from the disadvantage of poor acceptability due to a sand/oily feel in the mouth. Additionally, it needs a vehicle for reconstitution to be supplied along with the microcapsules It is evident that there is a commercial need for a pharmaceutical dosage form that effectively provides taste masking, without alteration of the release profile.
- the prior art fails to describe a pharmaceutical composition with a taste masking coating that provides for immediate release of the encapsulated active ingredient in solution, without the problems of leaching or swelling when exposed to an aqueous media in suspension at the typical pH of saliva.
- US Patent No. 6,221,402 assigned to Pfizer discloses a rapidly releasing and taste masking pharmaceutical dosage form for sildenafil and a process for the preparation of the same.
- this product uses an inner and outer coating wherein the inner coating coats the granules of sildenafil citrate and comprises of Eudragit NE30D, the outer coating comprising of two layers one made up of Eudragit ElOO and the other being a sugar coating layer.
- WO 04/087111 assigned to Ranbaxy discloses oral taste masked pharmaceutical compositions that include a core having an active ingredient coated with a mixture of polymeric film forming binders and inorganic carriers. Also provided are processes for preparing the oral taste masked pharmaceutical composition.
- WO 04/022037 assigned to Ranbaxy relates to taste masked dosage forms utilizing low amounts of taste masking polymer, and simple and economical processes for the preparation of the taste masked dosage forms.
- the taste-masked dosage form includes one or more drugs and one or more cationic polymers synthesized from dimethylaminoethyl methacrylate and neutral methacrylic acid esters.
- the wt/wt ratio of the drug to polymer is less than about one to two.
- US Application 2006/0159758 relates to coating compositions for taste masking and methods for applying the coating compositions to dosage forms to mask the taste of a medicinal substance.
- the taste masking coating compositions generally include a copolymer of acrylate and methacrylate with a quaternary ammonium group in combination with sodium carboxymethylcellulose and a polyvinyl alcohol-polyethylene glycol copolymer.
- a taste masked pharmaceutical composition of sildenafil citrate that includes use of a polyacrylic resin where in a cationic exchange occurs.
- a polyacrylic resin where in a cationic exchange occurs.
- the ready mix comprises of a polyacrylic resin which is cationic in nature. In addition it comprises carbomer and powdered cellulose.
- the polyacrylic resin does not belong to the class of methacrylic acid esters. It has free binding sites wherein the sildenafil citrate gets exchanged.
- the active pharmaceutical ingredient may be one or more of antibiotics, antihistamines, antiarthritics, anti psychotics, tranquillizers, antidiabetics, antipyretics, antiulcerants, antiasthmatics, antihypertensives, antianxiety, nonsteroidal antiinflammatory active ingredients and salts thereof.
- the active pharmaceutical ingredient may be one or more of clarithromycin, ciprofloxacin, acetaminophen, bambuterol, olanzapine, ranitidine, sildenafil, cefodoxime, amoxycillin, erythromycin, chlorpheniramine, cefuroxime and salts thereof.
- the active pharmaceutical ingredient may be present in the range of from about 5% w/w to about 90% w/w.
- the cationic polyacrylic resin comprising the ready mix does not belong to the methacrylate class of polymers and may be present in a concentration ranging from about 10% w/w to about 90°/0 w/w.
- the other excipients include mannitol which forms the base for chewable tablets.
- the concentration range for mannitol may vary from about 5% w/w to about 15% w/w.
- the composition may further include one or more pharmaceutically acceptable excipients which includes disintegrants like croscarmellose sodium, pH adjusters like citric acid monohydrate and sodium chloride, fillers like microcrystalline cellulose (Vivapur 102), sweetners like aspartame sucralose and sucrose, flavors like monoammonium glycerrhizinate, glidants and lubricants like magnesium stearate, talc and colloidal silicon dioxide (Aerosil), binders like PVP and colours.
- disintegrants like croscarmellose sodium, pH adjusters like citric acid monohydrate and sodium chloride
- sweetners like aspartame sucralose and sucrose
- flavors like monoammonium glycerrhizinate
- a process for the preparation of an oral taste masked composition of sildenafil citrate using an ion-exchange mechanism to mask the bitter taste of the drug includes forming a mask complex of sildenafil citrate by using Instacoat MK 9014 by using an aqueous process to obtains taste masked granules which are suitably sized followed by aqueous granulation of the masked complex with various excipients and then lubrication of the final mass before compression into tablets using suitable tooling.
- a method of treating a condition for which an active pharmaceutical ingredient is prescribed includes administering a taste masked pharmaceutical composition that includes a taste masked chewable tablet formulation.
- the present invention provides obvious benefits being simple and fast operational process for manufacturing said oral solid extended release pharmaceutical composition. While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
- the present invention provides taste masked chewable tablet compositions for bitter tasting drugs like sildenafil citrate.
- the said composition comprises the bitter drug sildenafil citrate in the form of a mask complex which is achieved by using a cationic exchange resin.
- the drug gets exchanged with the free sites in the polyacrylic cationic resin to form a taste masked complex.
- This taste masked complex is then incorporated into a formulation.
- the other excipients used to arrive at the final composition include disintegrants like croscarmellose sodium, pH adjusters like citric acid monohydrate and sodium chloride, fillers like microcrystalline cellulose (Vivapur 102), sweetners like aspartame sucralose and sucrose, flavors like monoammonium glycerrhizinate, glidants and lubricants like magnesium stearate, talc and colloidal silicon dioxide (Aerosil), binders like PVP and colours.
- pharmaceutically acceptable derivative means various pharmaceutical equivalent isomers, enantiomers, complexes, hydrates, polymorphs, and etc. of metoprolol succinate.
- composition includes but not limited to solutions and/or suspensions, dispersions, concentrates, ready mix, powders, granules, tablets, micro-tablets, capsules, and pellets, comprising metoprolol succinate or pharmaceutically acceptable derivatives thereof.
- terapéuticaally effective amount means an amount of the drug, which is capable of eliciting a physiological response in a human patient. More specifically, the term “therapeutically effective amount” means the amount of drug, which is capable of treating erectile dysfunction and related disorders.
- the medicament according to the present invention comprises a formulation substantially as herein described, and in particular a capsule, a tablet, micro-tablets, granules or pellets filled in capsule formulation, typically an extended or modified release tablet formulation substantially as hereinafter further described.
- a formulation according to the present invention provides a taste masked chewable dosage form, preferably tablets comprising taste masked sildenafil citrate or pharmaceutically acceptable derivatives thereof along with other pharmaceutically acceptable excipients wherein the taste masking is achieved through an ion-exchange mechanism
- a preferred embodiment of the present invention is a chewable tablet formulation comprising a pharmaceutically active agent (sildenafil citrate) along with suitable excipients.
- a pharmaceutically active agent sildenafil citrate
- suitable excipients for taste masking the bitter taste of sildenafil citrate by using an ion-exchange mechanism.
- the taste masked chewable tablet dosage form of sildenafil citrate according to the present invention may be formulated by mixing the drug with a polyacrylic cationic exchange resin that is commercially available as INSTAMASK R .
- This ready mix commercially available product comprises of a polyacrylic resin (cationic) ion-exchange resin, carbomer and powdered cellulose.
- the composition of the present invention may also comprise some drug that is not taste masked and added directly.
- the other excipients used include disintegrants like croscarmellose sodium, pH adjusters like citric acid monohydrate and sodium chloride, fillers like microcrystalline cellulose (Vivapur 102), sweetners like aspartame sucralose and sucrose, flavors like monoammonium glycerrhizinate, glidants and lubricants like magnesium stearate, talc and colloidal silicon dioxide (Aerosil), binders like PVP and colours.
- the present invention further comprises a process of preparing a pharmaceutical product, or a pharmaceutical composition, or a medicament substantially as herein before described.
- sildenafil citrate The total dose of sildenafil citrate is divided into two halves with one half being taste masked. The remaining half dose is added as such directly into the composition. This is done by mixing sildenafil citrate and Instacoat MK 9014 in purified water for 30 minutes, followed by stirring for a period of about 4 hours. The suspension is then centrifuged and dried in a fluidized bed drier. The resulting sildenafil citrate - Instacoat MK 9014 masked complex is sifted through Sieve No. 40.
- This dried masked complex is then granulated in a Rotary Mixer Granulator along with the remaining 50% sildenafil citrate, mannitol, microcrystalline cellulose, citric acid monohydrate, sodium chloride, aspartame, monoammonium glycerrhizinate, sucralose, sucrose, croscarmellose sodium and colours for a period of 15 minutes. All excipients are passed through Sieve No. 40 before use.
- the binder solution comprising povidone (PVPK30) in isopropyl alcohol is added to the dry mix and the mass granulated to obtain suitable granules.
- the granules are dried in a fluidized bed drier and sifted through Sieve No. 20.
- the granules are then transferred to an octagonal blender and mixed for 2 minutes.
- the granules are lubricated by addition of croscarmellose sodium, colloidal silicon dioxide, purified talc and flavours are mixed in the octagonal blender for 15 minutes. All excipients added at the lubrication stage are passed through Sieve No. 60. After blending of lubricants is completed for 15 minutes, magnesium stearate passed through Sieve No. 60 is added to the octagonal blender and the resulting mass is further mixed for 5 minutes. The lubricated mass is then compressed into tablets using suitable tooling.
- a flow chart depicting the process of manufacture is diagrammatically given below:
- sildenafil citrate mask complex a part of sildenafil citrate with Instacoat MK 9014 in purified water to form a sildenafil citrate mask complex.
- the resultant complex is dried and sized.
- This complex is then mixed with the remaining 50% sildenafil citrate, mannitol, microcrystalline cellulose, citric acid monohydrate, sodium chloride, aspartame, monoammonium glycerrhizinate, sucralose, sucrose, croscarmellose sodium and colours for a period of 15 minutes.
- the dry mix is granulated with a binder solution of povidone (PVPK30) in isopropyl alcohol, dried in a fluidized bed drier and sifted.
- povidone PVPK30
- the granules are lubricated by addition of croscarmellose sodium, colloidal silicon dioxide, purified talc and flavours and mixed in the octagonal blender for 15 minutes, followed by addition of magnesium stearate and further mixing for 5 minutes.
- the lubricated mass is then compressed into tablets using suitable tooling.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des compositions pharmaceutiques solides à croquer comprenant du citrate de sildénafil. Ledit citrate de sildénafil est un médicament très amer, si bien que les comprimés classiques comprennent un revêtement pelliculaire permettant d'améliorer son apparence esthétique et son acceptabilité. Lesdits comprimés à croquer sont généralement non revêtus, d'où la nécessité de masquer le goût amer du sildénafil afin de garantir leur acceptabilité par les patients. La présente invention parvient à masquer le goût du citrate de sildénafil grâce à l'utilisation d'une résine échangeuse d'ions qui forme un complexe et masque le goût amer du sildénafil. On incorpore ensuite le complexe de sildénafil au goût masqué d'échange d'ions à d'autres excipients, afin de formuler un comprimé à croquer en utilisant des arômes et d'autres ingrédients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2416MU2007 | 2007-12-10 | ||
IN2416/MUM/2007 | 2007-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009074995A1 true WO2009074995A1 (fr) | 2009-06-18 |
Family
ID=40755263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2008/000049 WO2009074995A1 (fr) | 2007-12-10 | 2008-01-25 | Compositions à croquer de citrate de sildénafil au goût masqué |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009074995A1 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011030351A2 (fr) | 2009-09-03 | 2011-03-17 | Rubicon Research Private Limited | Compositions pharmaceutiques au goût masqué |
WO2013077533A1 (fr) * | 2011-11-25 | 2013-05-30 | 한국유나이티드제약 주식회사 | Comprimés de citrate de sildénafil à croquer dans lesquels l'amertume est masquée, et procédé de fabrication associé |
KR20140077658A (ko) * | 2012-12-14 | 2014-06-24 | 한미약품 주식회사 | 포스포다이에스터라제-5 억제제를 포함하는 츄정 |
WO2014209022A1 (fr) * | 2013-06-28 | 2014-12-31 | Hanmi Pharm. Co., Ltd. | Formule de comprimé à mâcher comprenant du tadalafil ou l'un de ses sels pharmaceutiquement acceptables |
CN104352461A (zh) * | 2013-04-28 | 2015-02-18 | 南京海融医药科技有限公司 | 他达拉非的口服药物制剂 |
CN112826802A (zh) * | 2021-01-22 | 2021-05-25 | 上海普康药业有限公司 | 一种枸橼酸西地那非咀嚼片及其制备方法 |
CN113413388A (zh) * | 2021-06-30 | 2021-09-21 | 上海奥全生物医药科技有限公司 | 含有枸橼酸西地那非的药物组合物、制备方法及其应用 |
US11179331B1 (en) | 2020-04-21 | 2021-11-23 | Cure Pharmaceutcai Holding Corp | Oral soluble film containing sildenafil citrate |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040228830A1 (en) * | 2003-01-28 | 2004-11-18 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
WO2006000232A1 (fr) * | 2004-06-29 | 2006-01-05 | Fertin Pharma A/S | Chewing-gum liberant un alcaloide du tabac |
WO2006011044A1 (fr) * | 2004-07-22 | 2006-02-02 | Pfizer Products Inc. | Compositions a base de cyclodextrine amorphe |
US20070092553A1 (en) * | 2005-10-21 | 2007-04-26 | Pfab Lp | Compositions and methods of making rapidly dissolving lonically masked formulations |
-
2008
- 2008-01-25 WO PCT/IN2008/000049 patent/WO2009074995A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040228830A1 (en) * | 2003-01-28 | 2004-11-18 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
WO2006000232A1 (fr) * | 2004-06-29 | 2006-01-05 | Fertin Pharma A/S | Chewing-gum liberant un alcaloide du tabac |
WO2006011044A1 (fr) * | 2004-07-22 | 2006-02-02 | Pfizer Products Inc. | Compositions a base de cyclodextrine amorphe |
US20070092553A1 (en) * | 2005-10-21 | 2007-04-26 | Pfab Lp | Compositions and methods of making rapidly dissolving lonically masked formulations |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011030351A2 (fr) | 2009-09-03 | 2011-03-17 | Rubicon Research Private Limited | Compositions pharmaceutiques au goût masqué |
WO2011030351A3 (fr) * | 2009-09-03 | 2011-06-30 | Rubicon Research Private Limited | Compositions pharmaceutiques au goût masqué |
WO2013077533A1 (fr) * | 2011-11-25 | 2013-05-30 | 한국유나이티드제약 주식회사 | Comprimés de citrate de sildénafil à croquer dans lesquels l'amertume est masquée, et procédé de fabrication associé |
KR20140077658A (ko) * | 2012-12-14 | 2014-06-24 | 한미약품 주식회사 | 포스포다이에스터라제-5 억제제를 포함하는 츄정 |
KR101953735B1 (ko) | 2012-12-14 | 2019-03-04 | 한미약품 주식회사 | 포스포다이에스터라제-5 억제제를 포함하는 츄정 |
CN104352461A (zh) * | 2013-04-28 | 2015-02-18 | 南京海融医药科技有限公司 | 他达拉非的口服药物制剂 |
KR20150002453A (ko) * | 2013-06-28 | 2015-01-07 | 한미약품 주식회사 | 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제 |
WO2014209022A1 (fr) * | 2013-06-28 | 2014-12-31 | Hanmi Pharm. Co., Ltd. | Formule de comprimé à mâcher comprenant du tadalafil ou l'un de ses sels pharmaceutiquement acceptables |
KR102239291B1 (ko) | 2013-06-28 | 2021-04-14 | 한미약품 주식회사 | 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제 |
US11179331B1 (en) | 2020-04-21 | 2021-11-23 | Cure Pharmaceutcai Holding Corp | Oral soluble film containing sildenafil citrate |
CN112826802A (zh) * | 2021-01-22 | 2021-05-25 | 上海普康药业有限公司 | 一种枸橼酸西地那非咀嚼片及其制备方法 |
CN113413388A (zh) * | 2021-06-30 | 2021-09-21 | 上海奥全生物医药科技有限公司 | 含有枸橼酸西地那非的药物组合物、制备方法及其应用 |
CN113413388B (zh) * | 2021-06-30 | 2022-11-15 | 上海奥全生物医药科技有限公司 | 含有枸橼酸西地那非的药物组合物、制备方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
US4784858A (en) | Controlled release tablet | |
KR100768034B1 (ko) | 의약 조성물 | |
ES2606463T3 (es) | Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada | |
US20060039981A1 (en) | Taste masked dosage forms and processes for their preparation | |
WO2009074995A1 (fr) | Compositions à croquer de citrate de sildénafil au goût masqué | |
US20160271124A1 (en) | Formulations containing nalbuphine and uses thereof | |
JPH0530804B2 (fr) | ||
HUP0302086A2 (hu) | Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására | |
EP1194153A1 (fr) | Formulations pharmaceutiques liquides au gout masque. | |
JP2012514632A (ja) | 二段階放出型医薬懸濁剤 | |
JPH037238A (ja) | 持続性製剤用薬物放出制御膜 | |
JP2002541107A (ja) | トルペリソンを含有する経口投与のための薬学的製剤 | |
HUP0104394A2 (hu) | Granulált kristályos ibuprofént tartalmazó, bevont szemcsék | |
WO2004087111A1 (fr) | Compositions pharmaceutiques orales a gout masque | |
JP3221891B2 (ja) | 咀嚼可能な製薬錠剤調製のための回転造粒及び味覚遮蔽被覆加工 | |
JP2004529178A (ja) | 味遮蔽医薬組成物 | |
JP7146644B2 (ja) | サフィナミドを含む医薬組成物 | |
JP2021508316A (ja) | サフィナミドを含む医薬組成物 | |
US20190388354A1 (en) | Improved compositions and methods for reducing overdose | |
WO2017103631A1 (fr) | Composition pharmaceutique orale sous la forme de granules comprenant du métronidazole ou des dérivés de celui-ci et un agent de masquage du goût | |
EP2808019A1 (fr) | Composition de nitazoxanide améliorée et son procédé de préparation | |
JP2006509789A (ja) | 不安症治療法及び治療薬 | |
JP2004224767A (ja) | ベンジルアルコール誘導体含有徐放性経口製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08720110 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08720110 Country of ref document: EP Kind code of ref document: A1 |